[HTML][HTML] Human leukocyte antigen (HLA) and cancer immunotherapy: HLA-dependent and-independent adoptive immunotherapies
C Wang, C Xiong, YC Hsu, X Wang, L Chen - Annals of Blood, 2020 - aob.amegroups.org
… to immune checkpoint inhibitors than patients with low HLA-I … HLAs presents tumor antigens
to T cells to facilitate the … class II molecules expression were induced on certain tumor cells …
to T cells to facilitate the … class II molecules expression were induced on certain tumor cells …
Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope
… peptide antigens, in the context of human leukocyte antigen (HLA) class II molecules (HLA-II),
which through peptide-… This reactivity was inhibited by anti–HLA-DR blockade and no such …
which through peptide-… This reactivity was inhibited by anti–HLA-DR blockade and no such …
The potential of soluble human leukocyte antigen molecules for early cancer detection and therapeutic vaccine design
AL Kessler, MJ Bruno, SI Buschow - Vaccines, 2020 - mdpi.com
… such as immune checkpoint inhibition, therapeutic vaccines, … HLA-I molecules present
peptides derived from … be explained by differential induction of surface and soluble HLA-G, …
peptides derived from … be explained by differential induction of surface and soluble HLA-G, …
Role of human leukocyte antigen system as a predictive biomarker for checkpoint-based immunotherapy in cancer patients
… by tightly bound peptides derived from proteins degraded … ability of tumor cells to process
and present tumor antigens to … BRAF inhibitor vemurafenib strengthens the induction of HLA …
and present tumor antigens to … BRAF inhibitor vemurafenib strengthens the induction of HLA …
Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8+ T cells
W Shi, Q Qiu, Z Tong, W Guo, F Zou, Z Feng… - European journal of …, 2020 - Elsevier
… A1-restricted antigenic peptides, which exhibited prominent inhibiting … tumor antigens (a
“non-self” component) into the body, the antitumor effect can be initiated, which is mainly caused …
“non-self” component) into the body, the antitumor effect can be initiated, which is mainly caused …
Human leukocyte antigen class I antigen-processing machinery upregulation by anticancer therapies in the era of checkpoint inhibitors: a review
A Sadagopan, T Michelakos, G Boyiadzis… - JAMA …, 2022 - jamanetwork.com
… Defects in human leukocyte antigen (HLA) class I antigen-… of HLA class I antigen/tumor
antigen–derived peptide … protein (MAVS) by inducing transcription and cytoplasmic translocation …
antigen–derived peptide … protein (MAVS) by inducing transcription and cytoplasmic translocation …
[HTML][HTML] Immunological evaluation of a novel HLA-A2 restricted phosphopeptide of tumor associated Antigen, TRAP1, on cancer therapy
MH Lin, KY Shen, BS Liu, IH Chen, YP Sher, GC Tseng… - Vaccine: X, 2019 - Elsevier
… referred to as human leukocyte antigens class I molecules (… Therefore, the MHC I-bound
peptides derived from the tumor-… the cancer cells with this antigenic epitope or inhibit the tumor …
peptides derived from the tumor-… the cancer cells with this antigenic epitope or inhibit the tumor …
Human leukocyte antigen and tumor immunotherapy
DH Liu, FF Mou, M An, P Xia - … Journal of Oncology, 2023 - spandidos-publications.com
… and other types of tumor antigens has mainly focused on MHC class I molecule-restricted
antigens (106). However, … In addition, HLA-G can also inhibit the secretion of cytokines, induce …
antigens (106). However, … In addition, HLA-G can also inhibit the secretion of cytokines, induce …
HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine
Z Yu, W Liu, Y He, M Sun, J Yu, X Jiao, Q Han… - Journal of hematology & …, 2021 - Springer
… Cytotoxic T lymphocyte (CTL) epitopes derived from tumour antigens … -induced upregulation
of p38 phosphorylation level, we found that in DCs treated with TAK242 (a specific inhibitor …
of p38 phosphorylation level, we found that in DCs treated with TAK242 (a specific inhibitor …
Two unique HLA-A* 0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia
H He, Y Kondo, K Ishiyama, G Alatrash, S Lu, K Cox… - Leukemia, 2020 - nature.com
… induction of G1 cell cycle arrest [34]. In CML, targeting the peroxisome proliferator-activated
receptor alpha and gamma led to growth inhibition … used for MHC-I antigen presentation [36, …
receptor alpha and gamma led to growth inhibition … used for MHC-I antigen presentation [36, …